ZEPP
Zepp Health Corp
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeZepp Health delivered Q1 2026 revenue growth of 33.8% YoY ($51.5M) in line with guidance, with modest margin expansion and slightly reduced losses, but faces significant execution risk as stock has collapsed 70% in 2026 amid persistent unprofitability and analyst downgrades to neutral. Q2 2026 guidance of $63–68M implies decelerating growth (6–14% YoY), and the company must prove its 'quality over volume' pivot toward premium positioning and margin expansion ahead of August 26 earnings.
Red flags
- •Stock down 70% in 2026 despite 33.8% revenue growth, signaling investor skepticism about path to profitability
- •Persistent net losses ($17.9M adjusted in Q1 2026) with minimal sequential improvement despite revenue scale
- •Gross margins stuck in high 30s (~20 points below Garmin), limiting scalability and profitability potential
- •Analyst downgrade from buy to neutral in April 2026 citing unprofitability and macro headwinds
- •Q2 2026 guidance implies significant growth deceleration (6–14% vs. 33.8% in Q1), raising execution concerns
- •No confirmed Q2 2026 results published yet; upcoming August 26 earnings is critical inflection point with elevated execution risk
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).